> top > docs > PMC:7696151 > spans > 57137-59236 > annotations

PMC:7696151 / 57137-59236 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
1669 1419-1424 Gene denotes TGF-β Gene:7039
1670 1426-1454 Gene denotes transforming growth factor-β Gene:7124
1671 1490-1495 Gene denotes TGF-β Gene:21802
1672 107-113 Species denotes people Tax:9606
1673 1100-1105 Species denotes women Tax:9606
1674 1282-1290 Species denotes patients Tax:9606
1675 1532-1536 Species denotes mice Tax:10090
1676 1966-1970 Species denotes mice Tax:10090
1677 279-282 Chemical denotes HCQ MESH:D006886
1678 741-744 Chemical denotes HCQ MESH:D006886
1679 849-852 Chemical denotes HCQ MESH:D006886
1680 1145-1148 Chemical denotes HCQ MESH:D006886
1681 1205-1208 Chemical denotes HCQ MESH:D006886
1682 1472-1475 Chemical denotes HCQ MESH:D006886
1683 1690-1693 Chemical denotes HCQ MESH:D006886
1684 1901-1904 Chemical denotes HCQ MESH:D006886
1686 23-41 Disease denotes autoimmune disease MESH:D001327
1687 152-176 Disease denotes lymphocytic inflammation MESH:D007249
1688 227-237 Disease denotes xerostomia MESH:D014987
1689 290-306 Disease denotes Sjögren syndrome MESH:D012859
1690 762-778 Disease denotes Sjögren syndrome MESH:D012859
1691 1083-1099 Disease denotes Sjögren syndrome MESH:D012859
1692 1175-1186 Disease denotes eye dryness MESH:D014987
1693 1298-1313 Disease denotes Hypo-salivation MESH:D052456
1694 1328-1342 Disease denotes acinar atrophy MESH:D018267
1695 1347-1355 Disease denotes fibrosis MESH:D005355
1696 1775-1799 Disease denotes lymphocytic infiltration MESH:D017254
1697 1984-2008 Disease denotes lymphocytic infiltration MESH:D017254

LitCovid-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T99 23-41 Phenotype denotes autoimmune disease http://purl.obolibrary.org/obo/HP_0002960
T100 227-237 Phenotype denotes xerostomia http://purl.obolibrary.org/obo/HP_0000217

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T368 0-114 Sentence denotes Sjögren syndrome is an autoimmune disease with a strong negative impact on the quality of life of affected people.
T369 115-244 Sentence denotes The main features of the disease are lymphocytic inflammation and alterations in major salivary glands, causing xerostomia [103].
T370 245-399 Sentence denotes Even if preliminary results about HCQ use in Sjögren syndrome were not encouraging, to date it arises as one of the first-line drugs in disease treatment.
T371 400-690 Sentence denotes Indeed, an earlier prospective, a two-year double-blind crossover trial on 19 subjects correlated an annual intake of a dose of 400 mg/day with no significant improvements in clinical symptoms and signs of pathology, including tear and salivary gland activity, respect to the placebo [121].
T372 691-802 Sentence denotes However, a few years later, the first evidence of HCQ effectiveness in Sjögren syndrome treatment was reported.
T373 803-1036 Sentence denotes Annual treatment with a dose of 200 mg/day of HCQ showed anti-lymphoproliferative and anti-inflammatory effects, with a reduction of IgG and IgA immunoglobulins, anti-Sjögren autoantibodies, and erythrocyte sedimentation rates [100].
T374 1037-1297 Sentence denotes Moreover, the salivary flow rate increased in Sjögren syndrome women who received a daily dose of 400 mg of HCQ for 30 weeks [101], while eye dryness was alleviated by HCQ administration (6.5 mg/kg), as demonstrated by a prospective study on 32 patients [102].
T375 1298-1456 Sentence denotes Hypo-salivation deriving from acinar atrophy and fibrosis of salivary glands is often associated with over-expression of TGF-β (transforming growth factor-β).
T376 1457-1679 Sentence denotes Treatment with HCQ downregulated TGF-β levels in a randomized trial on NOD mice exposed to doses of 50 mg/kg/day intragastrically (i.g.) for 16 weeks, with significant results in delaying loss of saliva secretory function.
T377 1680-1806 Sentence denotes Moreover, HCQ intake was also accompanied by a decrease in autoantibody production and a lower lymphocytic infiltration [103].
T378 1807-2099 Sentence denotes These findings were confirmed by Wu, Pu, Yu and Li [104], showing that 8-weeks treatment with HCQ administered at a dose of 60 mg/kg i.g. in 40 randomized NOD mice led to lower lymphocytic infiltration, with a significant improvement in pathological changes in submandibular gland morphology.